Noubiap Jean Jacques, Mengnjo Michel K, Nicastro Nicolas, Kamtchum-Tatuene Joseph
From the Department of Medicine (J.J.N.), Groote Schuur Hospital and University of Cape Town, South Africa; Department of Medicine and Medical Specialties, Faculty of Medicine and Biomedical Sciences (M.K.M.), University of Yaoundé, Cameroon; Division of Neurorehabilitation, Department of Clinical Neurosciences (N.N.), Geneva University Hospitals, Switzerland; Brain Infections Group, Institute of Infection and Global Health (J.K.-T.), University of Liverpool; and Department of Neurology (J.K.-T.), The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Neurology. 2017 Oct 3;89(14):1516-1524. doi: 10.1212/WNL.0000000000004537. Epub 2017 Sep 1.
To summarize prevalence data on the neurologic complications of sickle cell disease (SCD) in Africa.
We searched EMBASE, PubMed, and African Index Medicus to identify all relevant articles published from inception to May 31, 2016. Each study was reviewed for methodologic quality. A random-effects model was used to estimate the prevalence of neurologic complications of SCD across studies.
Thirty-one studies were included. Methodologic quality was high or moderate in 90% of studies. Stroke, conditional and abnormal cerebral blood flow, seizures, and headache were the complications most frequently reported, with overall prevalence rates of 4.2%, 10.6%, 6.1%, 4.4%, and 18.9%, respectively. Some complications, like silent brain infarcts, peripheral neuropathies, neurocognitive deficits, or moyamoya disease, have been rarely or not studied at all in the African setting. Incidence data were scarce and of poor quality.
The burden of neurologic complications of SCD is important in Africa and most likely underestimated. A better evaluation of this burden requires larger prospective studies using standard up-to-date screening methods. Accessibility to diagnostic tools such as neuroimaging, transcranial Doppler, EEG, and neuropsychological evaluation, as well as to preventive and therapeutic interventions and trained health care providers, should be improved in routine clinical practice.
总结非洲镰状细胞病(SCD)神经并发症的患病率数据。
我们检索了EMBASE、PubMed和《非洲医学索引》,以识别从创刊至2016年5月31日发表的所有相关文章。对每项研究的方法学质量进行了评估。采用随机效应模型估计各研究中SCD神经并发症的患病率。
纳入31项研究。90%的研究方法学质量为高或中等。中风、条件性和异常脑血流、癫痫发作和头痛是最常报告的并发症,总体患病率分别为4.2%、10.6%、6.1%、4.4%和18.9%。一些并发症,如无症状脑梗死、周围神经病变、神经认知缺陷或烟雾病,在非洲地区很少或根本没有研究。发病率数据稀缺且质量较差。
SCD神经并发症在非洲的负担很重,很可能被低估。要更好地评估这一负担,需要采用标准的最新筛查方法进行更大规模的前瞻性研究。在常规临床实践中,应改善神经影像学、经颅多普勒、脑电图和神经心理学评估等诊断工具以及预防和治疗干预措施的可及性,并提高医疗保健人员的专业水平。